BioCryst Pharmaceuticals, Inc.
BCRX
$8.39
-$0.17-1.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 75.53% | 74.37% | 60.77% | 47.61% | 39.88% |
| Total Depreciation and Amortization | 13.61% | 9.72% | 5.06% | 5.24% | 11.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.34% | -20.47% | -24.73% | -33.70% | -31.58% |
| Change in Net Operating Assets | -23.57% | -89.42% | -169.38% | 7.08% | -1.45% |
| Cash from Operations | 120.05% | 74.48% | 45.32% | 49.37% | 31.60% |
| Capital Expenditure | 45.31% | 53.99% | 48.15% | 53.13% | -45.41% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 265.16% | 686.14% | 141.53% | 130.95% | 119.53% |
| Cash from Investing | 293.78% | 1,066.29% | 140.00% | 124.50% | 117.69% |
| Total Debt Issued | -- | -- | -- | -100.00% | -100.00% |
| Total Debt Repaid | -3,869.24% | 99.24% | 99.29% | 98.95% | 99.19% |
| Issuance of Common Stock | 118.76% | -10.08% | -53.25% | -66.79% | -75.01% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 16.03% | 82.30% | 78.21% | 79.56% | 79.39% |
| Cash from Financing | -1,429.71% | -115.87% | -117.73% | -112.33% | -104.32% |
| Foreign Exchange rate Adjustments | 364.73% | -222.88% | -358.56% | 420.47% | 404.17% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 114.38% | 129.45% | 96.84% | 44.26% | 46.46% |